Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results assessing the efficacy and safety of pembrolizumab in extensive stage small cell lung cancer patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 26 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 Jul 2017.
- 26 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Jul 2017.